Multiglandular Hormone Deficiency in a Patient with Systemic Capillary Leak Syndrome

por Then, Cornelia, Ritzel, Katrin, Seibold, Christa, Mann, Johannes F. E., Reincke, Martin
Publicado 2015

Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers

por Tye, Sok Cin, de Vries, Sieta T., Mann, Johannes F. E., Schechter, Meir, Mosenzon, Ofri, Denig, Petra, Heerspink, Hiddo J. L.
Publicado 2022

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial

por Mann, Johannes F. E., Fonseca, Vivian, Mosenzon, Ofri, Raz, Itamar, Goldman, Bryan, Idorn, Thomas, von Scholten, Bernt Johan, Poulter, Neil R.
Publicado 2018

Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial

por Nauck, Michael A., Buse, John B., Mann, Johannes F. E., Pocock, Stuart, Bosch‐Traberg, Heidrun, Frimer‐Larsen, Helle, Ye, Qing, Gray, Alastair
Publicado 2018

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

por Mann, Johannes F. E., Buse, John B., Idorn, Thomas, Leiter, Lawrence A., Pratley, Richard E., Rasmussen, Søren, Vilsbøll, Tina, Wolthers, Benjamin, Perkovic, Vlado
Publicado 2021

Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET...

por Baptiste, Paris J, Wong, Angel Y S, Schultze, Anna, Cunnington, Marianne, Mann, Johannes F E, Clase, Catherine, Leyrat, Clémence, Tomlinson, Laurie A, Wing, Kevin
Publicado 2022

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

por Floege, Jürgen, Covic, Adrian C., Ketteler, Markus, Mann, Johannes F.E., Rastogi, Anjay, Spinowitz, Bruce, Chong, Edward M.F., Gaillard, Sylvain, Lisk, Laura J., Sprague, Stuart M.
Publicado 2015

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

por Persson, Frederik, Bain, Stephen C., Mosenzon, Ofri, Heerspink, Hiddo J.L., Mann, Johannes F.E., Pratley, Richard, Raz, Itamar, Idorn, Thomas, Rasmussen, Søren, von Scholten, Bernt Johan, Rossing, Peter
Publicado 2021

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

por Green, Jennifer B, Mottl, Amy K, Bakris, George, Heerspink, Hiddo J L, Mann, Johannes F E, McGill, Janet B, Nangaku, Masaomi, Rossing, Peter, Scott, Charlie, Gay, Alain, Agarwal, Rajiv
Publicado 2022

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial

por Mosenzon, Ofri, Bain, Stephen C., Heerspink, Hiddo J. L., Idorn, Thomas, Mann, Johannes F. E., Persson, Frederik, Pratley, Richard E., Rasmussen, Søren, Rossing, Peter, von Scholten, Bernt Johan, Raz, Itamar
Publicado 2020

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

por Buse, John B., Bain, Stephen C., Mann, Johannes F.E., Nauck, Michael A., Nissen, Steven E., Pocock, Stuart, Poulter, Neil R., Pratley, Richard E., Linder, Martin, Monk Fries, Tea, Ørsted, David D., Zinman, Bernard
Publicado 2020

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

por Shaman, Ahmed M., Bain, Stephen C., Bakris, George L., Buse, John B., Idorn, Thomas, Mahaffey, Kenneth W., Mann, Johannes F.E., Nauck, Michael A., Rasmussen, Søren, Rossing, Peter, Wolthers, Benjamin, Zinman, Bernard, Perkovic, Vlado
Publicado 2021

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

por Rossing, Peter, Baeres, Florian M M, Bakris, George, Bosch-Traberg, Heidrun, Gislum, Mette, Gough, Stephen C L, Idorn, Thomas, Lawson, Jack, Mahaffey, Kenneth W, Mann, Johannes F E, Mersebach, Henriette, Perkovic, Vlado, Tuttle, Katherine, Pratley, Richard
Publicado 2023

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial

por Steinberg, William M., Nauck, Michael A., Zinman, Bernard, Daniels, Gilbert H., Bergenstal, Richard M., Mann, Johannes F.E., Steen Ravn, Lasse, Moses, Alan C., Stockner, Mette, Baeres, Florian M.M., Marso, Steven P., Buse, John B.
Publicado 2014

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparativ...

por Carrera, Fernando, Lok, Charmaine E., de Francisco, Angel, Locatelli, Francesco, Mann, Johannes F.E., Canaud, Bernard, Kerr, Peter G., Macdougall, Iain C., Besarab, Anatole, Villa, Giuseppe, Kazes, Isabelle, Van Vlem, Bruno, Jolly, Shivinder, Beyer, Ulrich, Dougherty, Frank C.
Publicado 2010

Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks—A Narrative Review

por Clase, Catherine M., Fu, Edouard L., Ashur, Aurneen, Beale, Rupert C.L., Clase, Imogen A., Dolovich, Myrna B., Jardine, Meg J., Joseph, Meera, Kansiime, Grace, Mann, Johannes F.E., Pecoits-Filho, Roberto, Winkelmayer, Wolfgang C., Carrero, Juan J.
Publicado 2020

Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk

por Böhm, Michael, Schumacher, Helmut, Werner, Christian, Teo, Koon K., Lonn, Eva M., Mahfoud, Felix, Speer, Thimoteus, Mancia, Giuseppe, Redon, Josep, Schmieder, Roland E., Sliwa, Karen, Marx, Nikolaus, Weber, Michael A., Laufs, Ulrich, Williams, Bryan, Yusuf, Salim, Mann, Johannes F. E.
Publicado 2022

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

por Perkovic, Vlado, Toto, Robert, Cooper, Mark E., Mann, Johannes F.E., Rosenstock, Julio, McGuire, Darren K., Kahn, Steven E., Marx, Nikolaus, Alexander, John H., Zinman, Bernard, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, von Eynatten, Maximillian, George, Jyothis T., Johansen, Odd Erik, Wanner, Christoph
Publicado 2020

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial

por Waijer, Simke W., Vart, Priya, Cherney, David Z. I., Chertow, Glenn M., Jongs, Niels, Langkilde, Anna Maria, Mann, Johannes F. E., Mosenzon, Ofri, McMurray, John J. V., Rossing, Peter, Correa-Rotter, Ricardo, Stefansson, Bergur V., Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J. L.
Publicado 2022

Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD

por Mann, Johannes F. E., Chang, Tara I., Cushman, William C., Furth, Susan L., Ix, Joachim H., Hou, Fan Fan, Knoll, Gregory A., Muntner, Paul, Pecoits-Filho, Roberto, Sarnak, Mark J., Tomson, Charles R. V., Craig, Jonathan C., Tunnicliffe, David J., Howell, Martin, Tonelli, Marcello, Cheung, Michael, Earley, Amy, Cheung, Alfred K.
Publicado 2021